Left Ventricular Systolic Function After 3 Months of SGLT2 Inhibitor Therapy in Heart Failure Patients with Reduced Ejection Fraction

Not much is known about the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on echocardiographic parameters of left ventricular (LV) systolic function in patients with heart failure and reduced ejection fraction (HFrEF). We prospectively included 59 outpatients with HFrEF: 41 patients...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiovascular translational research 2023-10, Vol.16 (5), p.987-998
Main Authors: Mustapic, Ivona, Bakovic, Darija, Susilovic-Grabovac, Zora, Borovac, Josip Andjelo
Format: Article
Language:English
Subjects:
Biomedical Engineering and Bioengineering
Biomedicine
Cardiology
Heart Failure - diagnostic imaging
Heart Failure - drug therapy
Human Genetics
Humans
Medicine
Medicine & Public Health
Original
Original Article
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Stroke Volume
Ventricular Dysfunction, Left - chemically induced
Ventricular Dysfunction, Left - diagnostic imaging
Ventricular Dysfunction, Left - drug therapy
Ventricular Function, Left
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Not much is known about the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on echocardiographic parameters of left ventricular (LV) systolic function in patients with heart failure and reduced ejection fraction (HFrEF). We prospectively included 59 outpatients with HFrEF: 41 patients received SGLT2i with OMT (SGLT2i+ group), whereas eighteen patients received OMT without SGLT2i (SGLT2i− group). Myocardial work index (MWI), 3D ejection fraction (3D LVEF), and global longitudinal strain (GLS) were measured at baseline and after 3 months following treatment. At 3-month follow-up, the SGLT2i+ group showed significantly greater improvement in MWI than the SGLT2i− group. In both groups, there was a significant improvement in 3D LVEF and LV GLS, circulating NT-proBNP levels, and NYHA functional class, with significantly greater improvement in the SGLT2i+ group. In conclusion, the addition of SGLT2i to fully optimized background medical therapy resulted in a greater improvement of LV systolic function among outpatients with HFrEF. Graphical abstract
ISSN:1937-5387
1937-5395
DOI:10.1007/s12265-023-10389-3